Circulating interleukin-16 in systemic lupus erythematosus

British Journal of Rheumatology

Volumn 37, Issue 12, 1998, Pages 1334-1337

  Lee, S ^b   Kaneko, H ^b   Sekigawa, I ^a   Tokano, Y ^b   Takasaki, Y ^b   Hashimoto, H ^b  

^a JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

^b NONE

Author keywords

CD4+ T cell activation; CD4+ T cell anergy; Human immunodeficiency virus; Interleukin 16; Systemic lupus erythematosus

Indexed keywords

INTERLEUKIN 16;

ADOLESCENT; ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; CD4-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-16; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED;

EID: 0032426680     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Center DM, Cruikshank WW. Modulation of lymphocyte migration by human lymphokines. I. Identification and characterization of chemoattractant activity for lymphocytes. J Immunol 1982;128:2563-8.
2. Cruikshank WW, Center DM. Modulation of lymphocyte migration by human lymphokines. II. Purification of a lymphotactic factor (LCF). J Immunol 1982;128: 2569-74.
3. + T lymphocytes and monocytes. J Immunol 1987;138:3817-25.
4. Rand T, Cruikshank WW, Center DM, Weller PE. CD4-mediated stimulation of human eosinophils: lymphocyte chemoattractant factor and other CD4-binding ligands elicit eosinophil migration. J Exp Med 1991;173:1521-8.
5. Cruikshank WW, Center DM, Nisar N, Wu M, Natke B, Theodore AC et al. Molecular and functional analysis of a lymphocyte chemoattractant factor: association of biologic function with CD4 expression. Proc Natl Acad Sci USA 1994;91:5109-13.
6. Parada NA, Cruikshank WW, Danis HL, Ryan TC, Center DM. IL-16-and other CD4 ligand-induced migration is dependent upon protein kinase C. Cell Immunol 1996;168:100-6.
7. Theodore AC, Center DM, Nicoll J, Fine G, Kornfeld H, Cruikshank WW. CD4 ligand IL-16 inhibits the mixed lymphocyte reaction. J Immunol 1996;157:1958-64.
8. Cruikshank WW, Lim K, Theodore AC, Cook J, Fine G, Weller PF et al. IL-16 inhibition of CD3-dependent lymphocyte activation and proliferation. J Immunol 1996;157:5240-8.
9. Center DM, Kornfeld H, Cruikshank WW. Interleukin 16 and its function as a CD4 ligand. Immunol Today 1996;17:476-81.
10. Horwitz DA, Stohl W, Gray JD. T lymphocyte, natural killer cells, cytokines, and immune regulation. In: Wallance DJ, Harn BH, eds. Dubois' lupus erythematosus. Baltimore: Williams & Wilkins, 1997:155-94.
11. + T-cells and deficient interleukin-2 production in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1990;55:285-96.
12. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
13. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, The Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
14. Klinman DM. B-cell abnormalities characteristic of systemic lupus erythematosus. In: Wallace DJ, Hahn BH, eds. Dubois' lupus erythematosus. Baltimore: Williams & Wilkins, 1997:195-206.
15. Inghirami G, Simon J, Balow JE, Tsokog GC. Activated T lymphocytes in the peripheral blood of patients with systemic lupus erythematosus induce B cells to produce immunoglobulin. Clin Exp Rheumatol 1988;6:269-76.
16. Huang YP, Miescher PA, Zubler RH. The interleukin 2 secretion defect in vitro in systemic lupus erythematosus is reversible in rested cultured T cells. J Immunol 1986;137:3515-20.
17. Sawada S, Hashimoto H, Lijima S, Tokano Y, Takei M, Shida M et al. Immunologic significance of increased soluble CD8/CD4 molecules in patients with active systemic lupus erythematosus. J Clin Lab Anal 1993; 7:141-6.
18. Tokano Y, Morimoto S, Hishikawa T et al. Subsets of activated T-cells in patients with systemic lupus erythematosus: the relation to cell cycle. Scand J Rheumatol 1997;26:37-42.
19. Stites DP, Casavant CH, McHugh TM et al. Flow cytometric analysis of lymphocyte phenotype in AIDS using monoclonal antibodies and simultaneous dual immunofluorescence. Clin Immunol Immunopathol 1986;38:161-77.
20. Meyaard L, Schuitemaker H, Miedema F. T-cell dysfunction in HIV infection: anergy due to defective antigen-presenting cell function? Immunol Today 1993;14:161-4.
21. Sekigawa I, Kaneko H, Hishikawa T, Hashimoto H, Hirose S, Kaneko Y et al. HIV infection and SLE: their pathogenic relationship. Clin Exp Rheumatol 1988;16: 176-80.
22. + T-cell anergy. Clin Exp Immunol 1997;109:41-7.
23. Sakihama T, Smolyar A, Reinherz EL. Oligomerization of CD4 is required for stable binding to class II major histocompatibility complex proteins but not for interaction with human immunodeficiency virus gp120. Proc Natl Acad Sci USA 1995;92:6444-8.
24. Linker-Israeli M. Cytokine abnormalities in human lupus. Clin Immunol Immunopathol 1992;63:10-2.
25. Via CS, Handwerger BS. B-cell and T-cell function in systemic lupus erythematosus. Curr Opin Rheumatol 1993;5:570-4.
26. Barcellini W, Rizzardi GP, Borghi MO et al. In vitro type-1 and type-2 cytokine production in systemic lupus erythematosus: lack of relationship with clinical disease activity. Lupus 1996;5:139-45.
27. Linker-Israeli M, Gray JD, Quismorio FP Jr, Horwitz DA. Characterization of lymphocytes that suppress IL-2 production in systemic lupus erythematosus. Clin Exp Immunol 1988;73:236-41.
28. Linker-Israeli M, Quismorio FP Jr, Horwitz DA. Further characterization of interleukin-2 production by lymphocytes of patients with systemic lupus erythematosus. J Rheumatol 1988;15:1216-22.
29. Linker-Israeli M, Casteel N. Partial purification of systemic lupus erythematosus-derived factors that suppress production of interleukin-2. J Rheumatol 1988; 15:952-8.